FK506-binding proteins (FKBPs) have emerged as a promising drug target due to their role in various diseases like psychiatric disorders, stress-related diseases, chronic pain and in microbial infections. Bicyclic [4.3.1.] aza-amides have proven to be a privileged scaffold for FKBPs and serve as valuable starting point for the development of potent FKBP inhibitors. The aim of this thesis was to further improve the affinity, selectivity and metabolic stability of this compound class. The first part of the thesis was dedicated to the metabolic stability of these ligands. A series of deuterated derivatives was synthesized and a metabolite distribution analysis was conducted. This enabled the localization of metabolic soft spots and narrowed it...
FK506-binding proteins (FKBPs) are evolutionarily conserved proteins that display peptidyl-prolyl is...
Selective inhibition of FKBP51 has emerged as possible novel treatment for diseases like major depre...
The design of efficient ligands remains a key challenge in drug discovery. In the quest for lead-lik...
FK506-binding proteins (FKBPs) have emerged as a promising drug target due to their role in various ...
The FK506-binding protein 51 (FKBP51) has emerged as an attractive new drug target for mood disorder...
FK506-binding proteins (FKBPs) are evolutionarily conserved proteins that display peptidyl-prolyl is...
Methyl groups can have profound effects in drug discovery but the underlying mechanisms are diverse ...
FK506-binding proteins (FKBPs) are evolutionarily conserved proteins that display peptidyl-prolyl is...
To create highly efficient inhibitors for FK506-binding proteins, a new asymmetric synthesis for pro...
The FK506-binding protein 51 (FKBP51) emerged as a key player in several diseases like stress-relate...
The design of efficient ligands remains a key challenge in drug discovery. In the quest for lead-lik...
In recent years the FK506-binding protein 51 (FKBP51) has emerged as a potential target for treating...
FK506-binding proteins (FKBPs) are evolutionarily conserved proteins that display peptidyl-prolyl is...
Selective inhibition of FKBP51 has emerged as possible novel treatment for diseases like major depre...
The design of efficient ligands remains a key challenge in drug discovery. In the quest for lead-lik...
FK506-binding proteins (FKBPs) have emerged as a promising drug target due to their role in various ...
The FK506-binding protein 51 (FKBP51) has emerged as an attractive new drug target for mood disorder...
FK506-binding proteins (FKBPs) are evolutionarily conserved proteins that display peptidyl-prolyl is...
Methyl groups can have profound effects in drug discovery but the underlying mechanisms are diverse ...
FK506-binding proteins (FKBPs) are evolutionarily conserved proteins that display peptidyl-prolyl is...
To create highly efficient inhibitors for FK506-binding proteins, a new asymmetric synthesis for pro...
The FK506-binding protein 51 (FKBP51) emerged as a key player in several diseases like stress-relate...
The design of efficient ligands remains a key challenge in drug discovery. In the quest for lead-lik...
In recent years the FK506-binding protein 51 (FKBP51) has emerged as a potential target for treating...
FK506-binding proteins (FKBPs) are evolutionarily conserved proteins that display peptidyl-prolyl is...
Selective inhibition of FKBP51 has emerged as possible novel treatment for diseases like major depre...
The design of efficient ligands remains a key challenge in drug discovery. In the quest for lead-lik...